BridgeBio Pharma Inc at Citi Biopharma Co-Panel Day (Virtual) Transcript
And thank you very much, and welcome to ATTR CM part 2. With us, I have from BridgeBio, CEO, Neil Kumar. And I also have Ananth Sridhar.
Questions & Answers
If you guys, I guess, first tell us about your efforts in cardiomyopathy, what's going on with acoramidis as far as where it stands right now since you reported results in December.
Yes. Well, thanks for the time, David. We appreciate the opportunity to be here. So our efforts in ATTR cardiomyopathy stem back almost to the advent of Bridge, maybe 5, 5.5 years ago. And at that point in time, as you well know, the mechanism of disease has been well described, some 140-odd mutations that seem to destabilize the tetramer transthyretin. And if you graph thermodynamic stability versus pathogenicity or penetrance, it was a fairly
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |